Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial

Cardiovasc Res. 2020 Oct 1;116(12):e152-e155. doi: 10.1093/cvr/cvaa247.
No abstract available

Keywords: Heart failure; Nitric oxide; Vericiguat; sGC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases / metabolism*
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • Disease Progression
  • Enzyme Activation
  • Enzyme Activators / adverse effects
  • Enzyme Activators / therapeutic use*
  • Heart Failure / drug therapy*
  • Heart Failure / enzymology
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Heterocyclic Compounds, 2-Ring / adverse effects
  • Heterocyclic Compounds, 2-Ring / therapeutic use*
  • Humans
  • Molecular Targeted Therapy
  • Nitric Oxide / metabolism
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Cardiovascular Agents
  • Enzyme Activators
  • Heterocyclic Compounds, 2-Ring
  • Pyrimidines
  • Nitric Oxide
  • ADCY10 protein, human
  • Adenylyl Cyclases
  • vericiguat